))
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
Manage episode 395008015 series 2838329
Content provided by VJHemOnc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJHemOnc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated.
In this podcast, leading experts Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, and Josu de la Fuente, PhD, FRCP, FRCPI, FRCPCH, FRCPath, Imperial College London, London, UK, discuss key updates in SCD presented at the 2023 ASH Annual Meeting and Exposition. The experts cover several topics, including the pathogenesis of SCD, novel agents being explored, and the growing role of gene therapies.
200 episodes
Share
